Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Forestviewon Oct 18, 2021 12:09pm

183 Views

Post# 34018420

Hexo CEO Removed

This article is actually very timely.

https://ca.finance.yahoo.com/news/hexo-ceo-exits-after-activist-investor-slams-performance-140151817.html

The Shareholders of Hexo (Canadian Cannibis) had the CEO removed for the following reasons

- recent dilutive financings
- the CEO's misalignment with shareholders
- lack of basic business skills to lead

Sound familiar? For all of you ticked off at Dan (dan@antibethera.com), send him a note and let him know as a shareholder that this is unacceptable. Send Walt Mackee (board chair) one too (although his email isn't made public). Both Dan and Walt got the lowest % of votes at the August AGM, so there is a lot of frustration brewing.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?